Drug Trial Radar · NCT05302947
COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU
Last checked: Nov 19, 2026Latest source record: Apr 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
154
Actual
Start
Feb 1, 2020
Primary completion
Aug 31, 2020
Study completion Jun 30, 2021
Sponsor
- Lead sponsor
- Pirogov Russian National Research Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- City Clinical Hospital No.52 of Moscow Healthcare Department
- First posted
- Mar 31, 2022
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a retrospective observational cohort study. About 1000 hospital charts of adult patients admitted to the hospital with mild-to-moderate COVID-19 from February to August 2020 were analyzed to evaluate the inflammatory markers and clinical outcomes. The aim of this study was to compare the observed results of targeted immunosuppressive therapy, anti-IL-6R (Tocilizumab), anti-IL-17A (Netakimab), and JAK1/JAK2 inhibitor (Baricitinib), with standard-of-care (SOC) therapy. The investigators hypothesize that, as compared to SOC therapy, all target drugs will demonstrate at least similar beneficial effects. This observation may additionally support a rational choice for mild-to-moderate COVID-19 treatment strategy, considering the general safety profile and patient-specific limitations.
Conditions
- COVID-19
- Mild to Moderate
Interventions
Baricitinib Oral TabletDrug
Baricitinib was administered at a dose of 4 mg once or twice per day for 3-8 days (5 days on average) depending on the individual patients' condition
Tocilizumab InjectionDrug
Tocilizumab was administered by a single intravenous dose of 400 mg
NetakimabDrug
Netakimab was administered by a single subcutaneous injection of 120 mg
Standard of care therapyOther
SOC treatment included hydroxychloroquine (400 mg twice on day 1, followed by 200 mg twice per day on days 5-10), azithromycin (500 mg once per day for 5 days), lopinavir-ritonavir (400/100 mg twice per day for 14 days), and low molecular-weight heparin according to personal indicators
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changing in the level of C-reactive proteinTime frame: 5 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
City Clinical Hospital No. 52 of the Department of Health of the City of Moscow
Moscow, Russia
Pirogov Russian National Research Medical University
Moscow, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.